Kintara Therapeutics (NASDAQ:KTRA) reported quarterly losses of $(2.10) per share which beat the analyst consensus estimate of $(3.16) by 33.54 percent. This is a 65 percent increase over losses of $(6.00) per share from the same period last year.
Salesforce Analyst Slashes Price Target By 14% To Reflect Broad-Based Macro Concerns In Front-Office Software
Wells Fargo analyst Michael Turrin maintained Salesforce Inc (NYSE:CRM) with an Overweight and reduced the price target from $220 to $190. Macro…